SG Americas Securities’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

SG Americas Securities’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,819	Closed	-$55K	–	3440
2024 Q1	$55K	Buy	+20,819	New	+$51.5K	﹤0.01%	2744
2023 Q2	–	Sell	-13,429	Closed	-$84K	–	3383
2023 Q1	$84K	Buy	13,429 +2,994	+29%	+$18.2K	﹤0.01%	2970
2022 Q4	$64K	Sell	10,435 -1,479	-12%	-$12K	﹤0.01%	2810
2022 Q3	$142K	Buy	11,914 +272	+2%	+$3.56K	﹤0.01%	2591
2022 Q2	$147K	Buy	+11,642	New	+$108K	﹤0.01%	2888
2022 Q1	–	Sell	-7,707	Closed	-$137K	–	3568
2021 Q4	$137K	Sell	7,707 -7,678	-50%	-$162K	﹤0.01%	2882
2021 Q3	$354K	Buy	+15,385	New	+$335K	﹤0.01%	2793
2021 Q1	–	Sell	-13,400	Closed	-$533K	–	3632
2020 Q4	$533K	Buy	+13,400	New	+$538K	﹤0.01%	1943

SG Americas Securities's KNTE Position: Q2 2024 in Review

SG Americas Securities sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 20,819 shares — an estimated $55K sold.

SG Americas Securities first reported a position in KNTE in Q4 2020 and held it in 8 quarters. The position peaked at $533K in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

SG Americas Securities reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
SG Americas Securities sold 20,819 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $55K.
SG Americas Securities first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
SG Americas Securities's Kinnate Biopharma Inc. Common Stock position peaked at $533K in Q4 2020.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.